Top

Published in:

01-03-2012 | Original Article

Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer

Authors: Shao-Bo Yang, Yun Du, Ben-Yan Wu, Shi-Ping Xu, Jun-Bao Wen, Min Zhu, Chang-Hao Cai, Ping-Chang Yang

Published in: Cancer Immunology, Immunotherapy | Issue 3/2012

Abstract

Tumor immune tolerance plays a critical role in tumor cell survival; the establishment of tumor immune tolerance is incompletely understood yet. Integrin alphavbeta6 (avb6) is involved in tumor growth and metastasis. This study aimed to observe the effect of avb6 on the development of tumor tolerance in colorectal cancer (CRC). In this study, 28 CRC patients were recruited. The frequencies of tolerogenic dendritic cells (TolDC), regulatory T cells (Treg), and CD8+ T cells in surgically removed CRC tissue were assessed by flow cytometry. The levels of avb6 in CRC tissue were measured by enzyme-linked immunoassay (ELISA). The effect of avb6 on inducing TolDCs and Tregs was evaluated with the cell culture model. The results showed that in surgically removed CRC tissue, we detected higher frequencies of TolDC and Tregs, lower frequency CD8+ T cells and high levels of avb6 as compared with non-CRC tissue. CRC protein extracts could induce TolDC development that could be blocked by anti-avb6 antibody. CRC-derived DCs could convert naïve CD4+ T cells to Tregs. Peripheral CD8+ T cells from CRC patients still retained the ability to produce granzyme B and to proliferate in response to CRC tumor antigen in culture that was abolished by the presence of CRC-derived Tregs. We conclude that CRC-derived avb6 is involved in the establishment of tumor immune tolerance in local tissues.

Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA et al (2010) Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222:350–366PubMedCrossRef

Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19:217–223PubMedCrossRef

Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10:554–567PubMedCrossRef

Pinchuk IV, Beswick EJ, Saada JI, Boya G, Schmitt D, Raju GS et al (2011) Human colonic myofibroblasts promote expansion of CD4+ CD25 high Foxp3+ regulatory T cells. Gastroenterology 140:2019–2030PubMedCrossRef

Coombes JL, Siddiqui KRR, Arancibia-Caírcamo CV, Hall J, Sun CM, Belkaid Y et al (2007) A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta- and retinoic acid-dependent mechanism. J Exp Med 204:1757–1764PubMedCrossRef

Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G et al (2003) Loss of integrin [alpha]v[beta]6-mediated TGF-[beta] activation causes Mmp12-dependent emphysema. Nature 422:169–173PubMedCrossRef

Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, Hart IR et al (2010) High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J Pathol 222:52–63PubMed

Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M et al (2011) NK cell adoptive transfer combined with ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol 186:3327–3335PubMedCrossRef

Augier S, Ciucci T, Luci C, Carle GF, Blin-Wakkach C, Wakkach A (2010) Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. J Immunol 185:7165–7173PubMedCrossRef

10.

Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307PubMedCrossRef

11.

Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, Wang JS et al (2008) Integrin alphavbeta6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci 99:879–887PubMedCrossRef

12.

Ghannad F, Nica D, Garcia Fulle MI, Grenier D, Putnins EE, Johnston S et al (2008) Absence of [alpha]v[beta]6 integrin is linked to initiation and progression of periodontal disease. Am J Pathol 172:1271–1286PubMedCrossRef

13.

Matta BM, Castellaneta A, Thomson AW (2010) Tolerogenic plasmacytoid DC. Eur J Immunol 40:2667–2676PubMedCrossRef

14.

Fontana L, Chen Y, Prijatelj P, Sakai T, Fassler R, Sakai LY et al (2005) Fibronectin is required for integrin alphavbeta6-mediated activation of latent TGF-beta complexes containing LTBP-1. FASEB J 19:1798–1808PubMedCrossRef

15.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity: roles in cancer suppression and promotion. Science 331:1565–1570PubMedCrossRef

16.

Ribas A (2010) Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 37:450–454PubMedCrossRef

17.

Campbell DJ, Koch MA (2011) Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 11:119–130PubMedCrossRef

18.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186–192PubMedCrossRef

19.

Antony PA (2002) Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25:202–206PubMedCrossRef

20.

Curtin JF (2008) Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 3:e1983PubMedCrossRef

21.

Taylor AW (2009) Review of the activation of TGF-beta in immunity. J leuko Biol 85:29–33PubMedCrossRef

22.

Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H et al (2003) Cytotoxic T-cell lymphoma arising in Behcet disease. Int J Hematol 77:282–285PubMedCrossRef

Title: Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer
Authors: Shao-Bo Yang
Yun Du
Ben-Yan Wu
Shi-Ping Xu
Jun-Bao Wen
Min Zhu
Chang-Hao Cai
Ping-Chang Yang
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1108-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice

Advances in cellular therapy: 6th international symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany

Response to the rebuttal letter of Kountouras and colleagues regarding the paper by Codolo et al. ‘HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response’

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells

A rebuttal to the potential anti-tumour benefit of Helicobacter pylori-induced neutrophil-activating protein

Keynote webinar | Spotlight on antibody–drug conjugates in cancer